KTTA News and Press, Pasithea Therapeutics Corp. From 08/11/22

Palm Beach, FL –– August 11, 2022 – FinancialNewsMedia.com News Commentary – Multiple Sclerosis (MS) is an immune-mediated disease affecting the central nervous system. It is characterized by demyelination, inflammation, degenerative changes such as p...

-- PAS002 is a proprietary DNA tolerizing vaccine construct encoding GlialCAM -- -- PAS002 effectively reduces disease severity, delays onset of illness, while also reducing relapse severity -- -- GlialCAM fragment is present in monkeypox virus, supporting a potential role in current va...

Stockholders Should Protect Upside in Potential Groundbreaking Therapies for MS, ALS and Other Large Unmet Medical Conditions from Activist’s Apparent Cash Grab Board Unanimously Recommends Stockholders to Sign, Date and Return GOLD Consent Revocation Card...

-- AUD $1 million (U.S $694,000) grant transferred as part of Alpha-5 Integrin, LLC transaction -- -- Provides approximately U.S. $694,000 of non-dilutive funding -- MIAMI BEACH, Fla., July 14, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) Pasithea Therapeuti...

Intends to WITHHOLD on All of Pasithea’s Sitting Directors at the Upcoming Annual Meeting of Stockholders Plans to Call a Special Meeting to Remove and Replace Pasithea’s Board of Directors, Which is Accountable for Misalignment, Poor Governance and Rap...

MIAMI BEACH, Fla., June 23, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological dis...

Pasithea Therapeutics (NASDAQ:KTTA) on Wednesday said it had acquired Alpha-5 Integrin LLC, a privately-held preclinical-stage company developing a monoclonal antibody for the treatment of neurodegenerative diseases such as amyotrophic lateral sclerosis and multiple sclerosis. Deal for $3.75M...

Palm Beach, FL – June 22, 2022 – FinancialNewsMedia.com News Commentary Neuroinflammatory disorder is the study of conditions where immune responses which damage components of the nervous system. It includes many rare neurological disease disorders like Alzheimer&#...

- Alpha-5 is a potentially first-in-class monoclonal antibody for the treatment of amyotrophic lateral sclerosis (ALS) and other neurological diseases - - Expands pipeline across Pasithea's core therapeutic areas to drive enhanced growth - - Closing consideration of 3.26 million shares ...

Pasithea Therapeutics’ (NASDAQ: KTTA) CEO, Dr. Tiago Reis Marques, a psychiatrist at one of the top psychiatry centers in the world, a fellow at Imperial College London and a lecturer at the Institute of Psychiatry, King’s College London, was featured in a recent Forbes art...